Sridharan Raghavan
Concepts (223)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Diabetes Mellitus, Type 2 | 23 | 2023 | 2221 | 4.080 |
Why?
| Cardiovascular Diseases | 8 | 2022 | 1859 | 1.880 |
Why?
| Blood Glucose | 15 | 2022 | 1957 | 1.490 |
Why?
| Veterans | 6 | 2023 | 1203 | 1.430 |
Why?
| Diabetes Mellitus | 6 | 2023 | 985 | 1.260 |
Why?
| Machine Learning | 4 | 2022 | 345 | 0.940 |
Why?
| Dementia, Vascular | 1 | 2022 | 20 | 0.890 |
Why?
| Myocardial Infarction | 3 | 2022 | 1134 | 0.880 |
Why?
| Hypertension | 2 | 2022 | 1245 | 0.830 |
Why?
| Coronary Artery Disease | 4 | 2022 | 695 | 0.780 |
Why?
| Life Style | 2 | 2021 | 436 | 0.770 |
Why?
| Risk Factors | 18 | 2023 | 9381 | 0.740 |
Why?
| Alzheimer Disease | 2 | 2023 | 513 | 0.740 |
Why?
| Early Medical Intervention | 1 | 2019 | 56 | 0.690 |
Why?
| Genetic Counseling | 1 | 2019 | 66 | 0.680 |
Why?
| Metformin | 1 | 2022 | 303 | 0.650 |
Why?
| Weight Loss | 2 | 2021 | 663 | 0.640 |
Why?
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2020 | 410 | 0.640 |
Why?
| Models, Statistical | 2 | 2021 | 651 | 0.630 |
Why?
| Hypoglycemic Agents | 4 | 2022 | 1055 | 0.620 |
Why?
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2019 | 228 | 0.610 |
Why?
| Atrial Fibrillation | 1 | 2022 | 392 | 0.610 |
Why?
| Secondary Prevention | 1 | 2019 | 257 | 0.600 |
Why?
| Behavior Therapy | 1 | 2019 | 249 | 0.590 |
Why?
| Adrenergic beta-Antagonists | 1 | 2019 | 334 | 0.580 |
Why?
| Genetic Predisposition to Disease | 5 | 2022 | 2359 | 0.560 |
Why?
| Genome-Wide Association Study | 8 | 2023 | 1376 | 0.550 |
Why?
| Antihypertensive Agents | 1 | 2019 | 465 | 0.540 |
Why?
| Research Design | 2 | 2021 | 1002 | 0.540 |
Why?
| Population Surveillance | 1 | 2019 | 439 | 0.530 |
Why?
| Humans | 41 | 2023 | 122796 | 0.450 |
Why?
| Risk Assessment | 3 | 2020 | 3213 | 0.440 |
Why?
| Social Support | 1 | 2016 | 547 | 0.430 |
Why?
| Mycobacterium tuberculosis | 4 | 2008 | 304 | 0.420 |
Why?
| Insulin Resistance | 3 | 2021 | 1192 | 0.410 |
Why?
| Fasting | 3 | 2020 | 266 | 0.410 |
Why?
| Polymorphism, Single Nucleotide | 8 | 2023 | 2127 | 0.410 |
Why?
| Metabolic Syndrome | 1 | 2015 | 395 | 0.380 |
Why?
| Retrospective Studies | 10 | 2023 | 13433 | 0.380 |
Why?
| Virulence Factors | 2 | 2008 | 143 | 0.370 |
Why?
| Aged | 12 | 2023 | 20495 | 0.350 |
Why?
| Incidence | 5 | 2020 | 2527 | 0.330 |
Why?
| Adult | 12 | 2022 | 32385 | 0.320 |
Why?
| Bacterial Proteins | 3 | 2008 | 775 | 0.310 |
Why?
| Middle Aged | 14 | 2023 | 28563 | 0.310 |
Why?
| Follow-Up Studies | 4 | 2019 | 4768 | 0.290 |
Why?
| Obesity | 3 | 2022 | 2786 | 0.270 |
Why?
| Survival Rate | 2 | 2019 | 1810 | 0.250 |
Why?
| United States | 7 | 2023 | 13272 | 0.240 |
Why?
| Male | 18 | 2023 | 59639 | 0.240 |
Why?
| Female | 18 | 2023 | 63629 | 0.230 |
Why?
| Selection Bias | 1 | 2022 | 35 | 0.220 |
Why?
| Biguanides | 1 | 2022 | 14 | 0.220 |
Why?
| Comorbidity | 2 | 2018 | 1600 | 0.210 |
Why?
| Calibration | 1 | 2022 | 140 | 0.210 |
Why?
| Causality | 1 | 2022 | 115 | 0.210 |
Why?
| Veterans Health | 2 | 2020 | 167 | 0.210 |
Why?
| Body Height | 1 | 2022 | 194 | 0.200 |
Why?
| Transcription Factors | 2 | 2016 | 1616 | 0.200 |
Why?
| Chromosome Mapping | 1 | 2022 | 518 | 0.200 |
Why?
| Entropy | 1 | 2021 | 38 | 0.200 |
Why?
| Coronary Disease | 1 | 2023 | 372 | 0.200 |
Why?
| Insurance Carriers | 1 | 2021 | 12 | 0.200 |
Why?
| Cause of Death | 2 | 2022 | 389 | 0.190 |
Why?
| Colonic Neoplasms | 1 | 2022 | 230 | 0.190 |
Why?
| Diabetic Retinopathy | 1 | 2022 | 156 | 0.190 |
Why?
| Macrophages | 5 | 2008 | 1334 | 0.190 |
Why?
| Probability | 1 | 2021 | 316 | 0.190 |
Why?
| Longitudinal Studies | 2 | 2018 | 2599 | 0.180 |
Why?
| Nutrition Surveys | 1 | 2021 | 240 | 0.180 |
Why?
| Precision Medicine | 1 | 2023 | 371 | 0.180 |
Why?
| Coronary Artery Bypass | 1 | 2021 | 226 | 0.170 |
Why?
| Exercise | 2 | 2021 | 1743 | 0.170 |
Why?
| Guidelines as Topic | 1 | 2021 | 273 | 0.170 |
Why?
| Cigarette Smoking | 1 | 2020 | 87 | 0.170 |
Why?
| Insurance, Health | 1 | 2021 | 259 | 0.170 |
Why?
| Diabetic Nephropathies | 1 | 2022 | 292 | 0.170 |
Why?
| Mendelian Randomization Analysis | 3 | 2023 | 52 | 0.160 |
Why?
| Patient Readmission | 1 | 2023 | 691 | 0.160 |
Why?
| Body Mass Index | 3 | 2022 | 2144 | 0.150 |
Why?
| Diabetes Complications | 1 | 2019 | 226 | 0.150 |
Why?
| Clinical Trials as Topic | 1 | 2022 | 985 | 0.150 |
Why?
| Bariatric Surgery | 1 | 2020 | 171 | 0.150 |
Why?
| Virulence | 3 | 2008 | 254 | 0.150 |
Why?
| Obesity, Morbid | 1 | 2020 | 204 | 0.140 |
Why?
| Tachycardia, Ventricular | 1 | 2018 | 174 | 0.140 |
Why?
| Risk | 2 | 2020 | 890 | 0.140 |
Why?
| Blood Pressure | 2 | 2022 | 1713 | 0.140 |
Why?
| Refugees | 1 | 2016 | 58 | 0.140 |
Why?
| Randomized Controlled Trials as Topic | 1 | 2021 | 1260 | 0.140 |
Why?
| Atherosclerosis | 1 | 2019 | 354 | 0.140 |
Why?
| Mortality | 1 | 2018 | 317 | 0.140 |
Why?
| Family Health | 1 | 2016 | 201 | 0.130 |
Why?
| Spouses | 1 | 2016 | 91 | 0.130 |
Why?
| Mutation Rate | 1 | 2015 | 25 | 0.130 |
Why?
| Physicians | 1 | 2023 | 824 | 0.130 |
Why?
| Percutaneous Coronary Intervention | 1 | 2021 | 535 | 0.130 |
Why?
| Gene Expression Regulation, Bacterial | 2 | 2008 | 291 | 0.130 |
Why?
| Emigrants and Immigrants | 1 | 2016 | 122 | 0.130 |
Why?
| Genotype | 1 | 2020 | 1943 | 0.130 |
Why?
| Oligonucleotide Array Sequence Analysis | 2 | 2015 | 783 | 0.130 |
Why?
| Defibrillators, Implantable | 1 | 2018 | 397 | 0.120 |
Why?
| Prognosis | 2 | 2019 | 3563 | 0.120 |
Why?
| Medication Adherence | 1 | 2019 | 575 | 0.120 |
Why?
| Cardiac Catheterization | 1 | 2018 | 577 | 0.120 |
Why?
| Exome | 1 | 2015 | 227 | 0.120 |
Why?
| Tuberculosis | 2 | 2008 | 266 | 0.110 |
Why?
| Insulin | 3 | 2021 | 2180 | 0.110 |
Why?
| Young Adult | 4 | 2021 | 11094 | 0.100 |
Why?
| Age Factors | 1 | 2019 | 3114 | 0.100 |
Why?
| Telemedicine | 1 | 2020 | 691 | 0.100 |
Why?
| Stroke | 1 | 2019 | 1090 | 0.090 |
Why?
| Sample Size | 2 | 2022 | 135 | 0.090 |
Why?
| Severity of Illness Index | 1 | 2018 | 2784 | 0.090 |
Why?
| Treatment Outcome | 2 | 2021 | 9692 | 0.090 |
Why?
| Genetic Variation | 1 | 2015 | 952 | 0.090 |
Why?
| Mycobacterium marinum | 1 | 2008 | 2 | 0.080 |
Why?
| Operon | 1 | 2008 | 62 | 0.080 |
Why?
| Gene Frequency | 2 | 2022 | 522 | 0.080 |
Why?
| Nod2 Signaling Adaptor Protein | 1 | 2008 | 30 | 0.080 |
Why?
| Time Factors | 1 | 2019 | 6682 | 0.080 |
Why?
| Lysosomes | 1 | 2008 | 136 | 0.080 |
Why?
| Glucagon-Like Peptide-1 Receptor | 2 | 2020 | 75 | 0.080 |
Why?
| Toll-Like Receptors | 1 | 2008 | 169 | 0.070 |
Why?
| Cohort Studies | 3 | 2023 | 5294 | 0.070 |
Why?
| Listeria monocytogenes | 1 | 2008 | 113 | 0.070 |
Why?
| Transcriptional Activation | 1 | 2008 | 360 | 0.070 |
Why?
| Phagocytosis | 1 | 2008 | 368 | 0.070 |
Why?
| Mice, Inbred C57BL | 4 | 2008 | 5020 | 0.070 |
Why?
| Genetic Loci | 2 | 2020 | 296 | 0.070 |
Why?
| Immunity, Cellular | 1 | 2008 | 276 | 0.070 |
Why?
| Glucose | 2 | 2021 | 968 | 0.070 |
Why?
| Transcription, Genetic | 2 | 2008 | 1355 | 0.070 |
Why?
| Sensitivity and Specificity | 2 | 2019 | 1855 | 0.060 |
Why?
| Promoter Regions, Genetic | 1 | 2008 | 1188 | 0.060 |
Why?
| Phenotype | 2 | 2022 | 3070 | 0.060 |
Why?
| Clonal Evolution | 1 | 2023 | 26 | 0.060 |
Why?
| Mycobacterium Infections, Nontuberculous | 1 | 2008 | 334 | 0.060 |
Why?
| Hematopoiesis | 1 | 2023 | 179 | 0.050 |
Why?
| Skilled Nursing Facilities | 1 | 2023 | 128 | 0.050 |
Why?
| Linkage Disequilibrium | 1 | 2022 | 279 | 0.050 |
Why?
| Europe | 1 | 2022 | 369 | 0.050 |
Why?
| United Kingdom | 1 | 2022 | 260 | 0.050 |
Why?
| Biological Specimen Banks | 1 | 2022 | 107 | 0.050 |
Why?
| Albuminuria | 1 | 2022 | 195 | 0.050 |
Why?
| Consensus | 1 | 2023 | 554 | 0.050 |
Why?
| Haplotypes | 1 | 2022 | 482 | 0.050 |
Why?
| Mice | 5 | 2008 | 15888 | 0.050 |
Why?
| Fee-for-Service Plans | 1 | 2021 | 94 | 0.050 |
Why?
| Genome, Human | 1 | 2022 | 392 | 0.050 |
Why?
| Cholesterol, LDL | 1 | 2022 | 326 | 0.050 |
Why?
| Sodium | 1 | 2020 | 204 | 0.040 |
Why?
| Evidence-Based Medicine | 1 | 2023 | 731 | 0.040 |
Why?
| Decision Trees | 1 | 2018 | 95 | 0.040 |
Why?
| Glomerular Filtration Rate | 1 | 2022 | 697 | 0.040 |
Why?
| Medicare | 1 | 2023 | 767 | 0.040 |
Why?
| Gene Expression Regulation | 1 | 2008 | 2491 | 0.040 |
Why?
| Exercise Test | 1 | 2021 | 588 | 0.040 |
Why?
| ROC Curve | 1 | 2019 | 494 | 0.040 |
Why?
| Genomics | 1 | 2022 | 714 | 0.040 |
Why?
| Homeostasis | 1 | 2021 | 596 | 0.040 |
Why?
| Feasibility Studies | 1 | 2020 | 780 | 0.040 |
Why?
| Patient Discharge | 1 | 2023 | 842 | 0.040 |
Why?
| United States Department of Veterans Affairs | 1 | 2020 | 564 | 0.040 |
Why?
| Massachusetts | 1 | 2016 | 140 | 0.040 |
Why?
| Odds Ratio | 1 | 2019 | 1043 | 0.040 |
Why?
| Molecular Sequence Annotation | 1 | 2016 | 91 | 0.040 |
Why?
| Introns | 1 | 2016 | 236 | 0.030 |
Why?
| Animals | 5 | 2008 | 34133 | 0.030 |
Why?
| Glucose-6-Phosphatase | 1 | 2015 | 32 | 0.030 |
Why?
| Enhancer Elements, Genetic | 1 | 2016 | 162 | 0.030 |
Why?
| Cells, Cultured | 3 | 2008 | 4162 | 0.030 |
Why?
| Hospitalization | 1 | 2023 | 1914 | 0.030 |
Why?
| Quantitative Trait Loci | 1 | 2016 | 328 | 0.030 |
Why?
| Pilot Projects | 1 | 2018 | 1477 | 0.030 |
Why?
| Double-Blind Method | 1 | 2017 | 1711 | 0.030 |
Why?
| Proportional Hazards Models | 1 | 2016 | 1184 | 0.030 |
Why?
| Logistic Models | 1 | 2018 | 1995 | 0.030 |
Why?
| Mutation | 1 | 2023 | 3493 | 0.030 |
Why?
| Genetic Association Studies | 1 | 2015 | 383 | 0.030 |
Why?
| Adolescent | 2 | 2021 | 18948 | 0.030 |
Why?
| Mass Screening | 1 | 2019 | 1095 | 0.030 |
Why?
| Prospective Studies | 1 | 2023 | 6704 | 0.030 |
Why?
| Reproducibility of Results | 1 | 2019 | 2977 | 0.030 |
Why?
| Islets of Langerhans | 1 | 2016 | 749 | 0.020 |
Why?
| Electronic Health Records | 1 | 2016 | 842 | 0.020 |
Why?
| Aged, 80 and over | 1 | 2021 | 6845 | 0.020 |
Why?
| Pregnancy | 1 | 2021 | 5854 | 0.020 |
Why?
| CARD Signaling Adaptor Proteins | 1 | 2008 | 17 | 0.020 |
Why?
| Registries | 1 | 2016 | 2020 | 0.020 |
Why?
| Caspase 1 | 1 | 2008 | 143 | 0.020 |
Why?
| Adaptor Proteins, Vesicular Transport | 1 | 2008 | 49 | 0.020 |
Why?
| Cytoskeletal Proteins | 1 | 2008 | 147 | 0.020 |
Why?
| Apoptosis Regulatory Proteins | 1 | 2008 | 198 | 0.020 |
Why?
| Myeloid Differentiation Factor 88 | 1 | 2008 | 99 | 0.020 |
Why?
| Macrophage Activation | 1 | 2008 | 169 | 0.020 |
Why?
| Hemolysis | 1 | 2008 | 167 | 0.020 |
Why?
| Biomarkers | 1 | 2017 | 3662 | 0.020 |
Why?
| NLR Family, Pyrin Domain-Containing 3 Protein | 1 | 2008 | 152 | 0.020 |
Why?
| Gene Silencing | 1 | 2008 | 178 | 0.020 |
Why?
| Interleukin-18 | 1 | 2008 | 229 | 0.020 |
Why?
| Interleukin-1beta | 1 | 2008 | 383 | 0.020 |
Why?
| Genetic Complementation Test | 1 | 2005 | 62 | 0.020 |
Why?
| Two-Hybrid System Techniques | 1 | 2005 | 58 | 0.020 |
Why?
| Culture Media, Conditioned | 1 | 2005 | 114 | 0.020 |
Why?
| Genes, Bacterial | 1 | 2005 | 165 | 0.020 |
Why?
| Antigens, Bacterial | 1 | 2005 | 120 | 0.020 |
Why?
| Multigene Family | 1 | 2005 | 200 | 0.020 |
Why?
| Carrier Proteins | 1 | 2008 | 740 | 0.010 |
Why?
| Conserved Sequence | 1 | 2003 | 220 | 0.010 |
Why?
| Plasmids | 1 | 2003 | 358 | 0.010 |
Why?
| Protein Transport | 1 | 2003 | 418 | 0.010 |
Why?
| Calcium | 1 | 2008 | 1244 | 0.010 |
Why?
| Child | 1 | 2021 | 19561 | 0.010 |
Why?
| Viral Proteins | 1 | 2003 | 300 | 0.010 |
Why?
| Mice, Knockout | 1 | 2008 | 2737 | 0.010 |
Why?
| Amino Acid Sequence | 1 | 2005 | 2123 | 0.010 |
Why?
| Gene Expression Profiling | 1 | 2008 | 1625 | 0.010 |
Why?
| Molecular Sequence Data | 1 | 2005 | 2933 | 0.010 |
Why?
| Inflammation | 1 | 2008 | 2598 | 0.010 |
Why?
| Models, Biological | 1 | 2003 | 1756 | 0.010 |
Why?
| Signal Transduction | 1 | 2008 | 4902 | 0.010 |
Why?
| Disease Models, Animal | 1 | 2003 | 3799 | 0.010 |
Why?
|
|
Raghavan's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|